One key challenge in clinical trials is patient access: reaching the right patients, ensuring easy access to trials, and making it easy for patients to continue participation. The industry is undergoing a shift in this regard. Historically, clinical trials were perceived to be focused on scientific outcomes over patient experience. The patients and their perspectives weren’t factored into the whole process of therapeutic development.
Then, in 2012, the FDA started working on the Patient-Focused Drug Development Initiative. Today, the FDA defines patient-focused drug development (PFDD) as “a systematic approach to help ensure that patients’ experiences, perspectives, needs, and priorities are captured and meaningfully incorporated into drug development and evaluation.” That can start when you design a clinical trial.
As a standard, we need to build patient-centric clinical trials so we can improve patient recruitment, engagement, and retention for better outcomes. Take a closer look at how you as a trial sponsor can implement technology to support that process.
As a sponsor, you can streamline early data collection when you provide one digital platform that connects sites and sponsors remotely. A digital platform can benefit sites by simplifying data aggregation during pre-screening processes. Instead of collecting pre-screening data in disparate systems – on paper, in Excel, etc. – sites can use a digital system to quickly and accurately enter and organize useful data.
When you can view that de-identified data on your end of the platform, you can pull actionable information while the pre-screening process is ongoing, so it’s not too late to use it.
Of course, it does matter what information sites are inputting and sponsors are able to view. You should think critically about what information will be most valuable to collect, both on an individual trial and across your portfolio. Then, during the study startup process, it’s important to set expectations around the digital pre-screening process with site teams. Introduce the platform sites will be using, and outline the data they should be capturing during pre-screening. As a starting point, diversity data, reasons declined, and I/E criteria failure information can all be valuable data points.
Suddenly, as recruitment ramps up, you’ll be able to answer critical questions such as:
Using this early data, you can address risks and burdens perceived by patients, as well as barriers to their enrollment, while recruitment is ongoing. That’s how you start to change the course of your recruitment and enrollment.
Simply put, when your clinical trial design is site-centric, it naturally becomes patient-centric. If you build technology into your trial design that provides sites with tools to communicate more effectively and complete visit tasks more efficiently, you free sites up to focus on patient care. That means sites can communicate better with patients, build stronger relationships with patients, and provide overall better care, all of which can improve patient experience and retention.
So what tools do sites need within the platforms where they’re managing patients? Consider tools and formatting such as:
When site workflows are improved, patients benefit.
Having one platform that enables sites to streamline workflows across multiple trials frees up time to care for patients. On a greater level, it creates more time to identify patients more efficiently for trials that match their needs. This prevents patients who have been referred to trials or who have self-identified for trials from getting stuck in a holding pattern, with no one contacting them about the next step forward in their trial search.
What cross-trial recruitment capabilities do sites need in their technology for better workflows? Consider functionalities such as:
With the right technology enabling patient-centric clinical trials, you can anticipate better patient retention and engagement, increased patient access, and faster patient recruitment. Your sites benefit because they can improve their workflows while providing better patient care. You benefit because you can identify and address barriers to enrolling diverse populations while they are appearing. And patients benefit because they can access trials faster and more efficiently, while receiving the best care from their site teams.